Clinical Trial Update: SD, IL-13 Production Rate in IPF [Phase 2]

View source ↗

Summary

Phase 2 trial update in idiopathic pulmonary fibrosis investigating SD and IL-13 production rate.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: COMPLETED